Ascendis Pharma targets €200M SKYTROFA revenue and expands YORVIPATH globally in 2025
CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX
NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / WHY: New York, N.Y., February 12, 2025. Rosen Law Firm, a global investor rights law ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Royalty Pharma (RPRX), Waters (WAT) and OrganiGram Holdings (OGI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Royalty Pharma (RPRX – Research Report), ...
beautypackaging21h
ICONS|ICS Earns 2025 EcoVadis Platinum Medal for the 3rd Consecutive Year
Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies. You can obtain detailed information about the use of cookies ...
Inside Takeda’s Plasma-Derived Therapy Ecosystem
Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
Invesco EQV International Equity Fund Q4 2024 Commentary
Class A shares underperformed the MSCI ACWI ex USA Index. During the quarter, we initiated four new positions and exited one ...
Asian News International on MSN2d
Brandscouncil Ratings recently felicitated corporates with its World Best Brands & Business Awards 2024, Dubai & Asia Editions
Brandscouncil Ratings felicitated 100+ Corporates with World Best Brands & Business Awards'2024, World Real Estate, ...